About Us
Tianjin Orilife Biopharma Co., Ltd.
Tianjin Orilife Biopharma Co., Ltd. is a high-tech enterprise dedicated to the R&D, production, and sales of essential raw materials for molecular diagnostics and nucleic acid drug synthesis, including nucleosides, nucleotides and phosphoramidite, nucleic acid drug synthesis carriers, and nucleic acid drug delivery carriers.
Orilife built a production facility with full DCS (Distributed Control System) automatic control and strictly follows ISO9001, ISO14001, and ISO45001 management standards to control raw material procurement, process control, finished product testing, environmental protection, safety production, and more. The plant has an annual production capacity of 6000kg, equipped with more than 50 reactors of different specifications from 100L to 5000L to meet the customized production needs of customers in different batches.
Orilife’s testing center is CNAS-accredited and boasts domestically leading chemical modification, purification technologies, and quality control platforms. Rianlon Corporation (stock code: 300596) serves as the controlling shareholder of Orilife. Relying on Rianlon’s expertise in engineering design, large-scale plant construction, production management, and quality assurance in fine chemical production, Orilife aims to evolve from a manufacturer with a comprehensive range of nucleic acid drug raw materials and molecular diagnostic materials into a world-class supplier and technical service provider of nucleic acid drug raw materials.
Strong Partnership
Honorary Qualifications
Development History
August 2020
Rianlon Corporation and Suzhou Genepharma Co., Ltd. have jointly launched a project focused on "raw Gene materials for small nucleic acid drugs."
December 2020
Lianlong Life Sciences Division Officially Established
April 13, 2021
Tianjin Orilife Biopharma Co., Ltd. was established, and Lianlong joins hands with Gema Gene to enter the field of small nucleic acid drug raw materials.
September 2022
The pilot-scale R&D project for Ouref nucleotide monomers has passed the acceptance inspection by China Communications Construction Company.
December 2022
Ouref Nucleotide Monomer Pilot Production
Social Responsibility
Become a world-class enterprise that is trusted by customers, proud of its employees, respected by society, and committed to sustainable development.
Service hotline:
Company email:
Share
